Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. The actions ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals get in the way of its progress. With recent indication additions, breast ...

Applications are now being accepted, with $500,000 in grants to be awarded to projects focused on improving health equity in Canada Novartis Pharmaceuticals Inc. (CNW Group/Novartis ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta Therapeutics’ Elevidys and Novartis ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novartis will pay $800 million upfront to acquire Regulus Therapeutics, a San Diego biotechnology company ...

Incyte (NASDAQ:INCY) and Novartis AG (NYSE:NVS) reached a settlement regarding royalty payments in an existing collaboration between the companies for blood-cancer treatment Jakafi. In a filing on ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus ...

(RTTNews) - Regulus Therapeutics (RGLS) has entered into an agreement and plan of merger with Novartis AG and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told ...

You can reach Jason on Signal at JasonMast.05. Novartis said Wednesday it would buy Regulus Therapeutics and its experimental kidney drug for $800 million upfront. The immediate payout is more ...

Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO) Annual ...